Skip to main content
    A

    AbbVie Inc (ABBV)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - GENERAL • NYSE

    $292.91
    -1.64 (-0.56%)

    Market Cap: $521.50B

    Last updated: Nov 17, 2026 at 4:41 PM ET

    AbbVie Inc (ABBV) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    AbbVie (ABBV) has a market cap of $521.50B and an enterprise value of $591.63B. Its trailing P/E of 22.8x is above its 10-year median of 12.5x.

    Total Valuation

    Enterprise value is 13.45% above the market cap, as debt exceeds cash.

    Market Cap$521.50B
    Enterprise Value$591.63B
    Latest price (Nov 17, 2026)$292.91

    Key Dates

    The next earnings report is expected on Feb 2, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Jan 15, 2027.

    Next Earnings DateFeb 2, 2027 (expected)
    Last Earnings DateOct 30, 2026
    Next Ex-Dividend DateJan 15, 2027
    Next Payment DateFeb 16, 2027
    Fiscal Year EndDecember

    Share Statistics

    The share count held steady in the quarter ended Sep 30, 2026 and held steady over 2 years.

    Shares Outstanding1.77B
    Shares Change (YoY)0.00%
    Shares Change (QoQ)0.00%
    Share Count Growth (2Y CAGR)0.00%

    Valuation Ratios

    The price to sales ratio is 7.8x. Its year-end P/E ranged from 9.9x to 22.8x from 2016 to 2025.

    P/E Ratio22.8x
    Forward P/E20.5x
    P/S Ratio7.8x
    Forward P/S7.7x
    P/FCF Ratio27.5x
    P/OCF Ratio26.0x
    PEG Ratio1.4

    Valuation history and multiples

    Enterprise Valuation

    Counting debt and cash, the company is valued at 25.4x EBITDA and 31.2x free cash flow.

    EV / Earnings57.2x
    EV / Sales9.0x
    EV / EBITDA25.4x
    EV / EBIT38.2x
    EV / FCF31.2x

    Price Statistics

    The stock is up 29.04% over 52 weeks and trades 6.01% above its 50-day average.

    Beta (1Y)-0.01
    52-Week Change+29.04%
    1-Month Change+3.62%
    3-Month Change+10.80%
    6-Month Change+38.00%
    5-Year Change+157.16%
    10-Year Change+428.67%
    Total Return (1Y)+32.09%
    Total Return (3Y CAGR)+32.52%
    Total Return (5Y CAGR)+24.37%
    Return vs SPY (1Y)+16.65%
    Max Drawdown (1Y)-15.74%
    Max Drawdown (3Y)-20.73%
    Sharpe Ratio (1Y)0.99
    Correlation with SPY (1Y)-0.01
    50-Day Average$276.31
    200-Day Average$239.43
    52-Week Range$188.25 to $302.93
    RSI (14 Days)59.2
    Average Volume (20 Days)5.15M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 0.87x current liabilities.

    Current Ratio0.87x
    Quick Ratio0.75x
    Debt / EBITDA3.49x
    Debt / FCF4.29x

    Returns and Efficiency

    Return on invested capital is 16.39% over the last 12 months, against a 5-year average of 11.67%.

    Return on Assets (ROA)7.01%
    Return on Invested Capital (ROIC)16.39%
    Return on Capital Employed (ROCE)14.81%
    ROA (5Y Average)5.27%
    ROIC (5Y Average)11.67%
    Asset Turnover0.47x
    Inventory Turnover3.97x
    Receivables Turnover4.83x
    Cash Conversion Cycle-430 days

    Taxes

    Income tax took 19.24% of pretax income over the last 12 months.

    Income Tax (TTM)$2.47B
    Effective Tax Rate19.24%

    Scores

    ABBV has an Altman Z-Score of 2.64, in the grey zone from 1.81 to 2.99, and a Piotroski F-Score of 7 of 9, in the average band of 3 to 7.

    Altman Z-Score2.64
    Altman Z ZoneGrey
    Piotroski F-Score7 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $66.01B over the last 12 months is up 10.68% from the 12 months before.

    Revenue$66.01B
    Revenue Growth (YoY)+10.68%
    Gross Profit$45.33B
    Operating Income$21.23B
    Pretax Income$12.81B
    Net Income$10.35B
    EBITDA$23.16B
    EBIT$15.49B
    Reported EPS (TTM)$12.83

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Cash and Equivalents$10.77B
    Total Debt$80.90B
    Net Debt$70.13B
    Net Debt Per Share$39.64
    Working Capital-$5.62B
    Shareholder Equity-$4.58B
    Tangible Book Value-$99.03B
    Total Assets$147.68B
    Total Liabilities$152.22B

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $1.22B of capital spending, operating cash flow left $18.87B of free cash flow.

    Operating Cash Flow$20.09B
    Capital Expenditures$1.22B
    Free Cash Flow$18.87B
    FCF Per Share$10.68
    Depreciation and Amortization$7.67B
    Dividends Paid$12.14B
    Share Repurchases$1.53B

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is 32.16%, against a 5-year average of 25.49%.

    Gross Margin68.67%
    Operating Margin32.16%
    Pretax Margin19.41%
    Net Margin15.68%
    EBITDA Margin35.08%
    EBIT Margin23.47%
    FCF Margin28.59%
    Gross Margin (5Y Average)66.44%
    Operating Margin (5Y Average)25.49%
    Net Margin (5Y Average)12.89%

    Growth

    Revenue grew 1.75% a year over 3 years, and EPS fell 10.16% a year.

    Revenue Growth (3Y CAGR)+1.75%
    Revenue Growth (5Y CAGR)+5.95%
    EPS Growth (3Y CAGR)-10.16%
    EPS Growth (5Y CAGR)-0.99%
    FCF Growth (3Y CAGR)-9.76%
    FCF Growth (5Y CAGR)+1.19%
    Operating Income Growth (3Y CAGR)-5.94%

    Revenue and profit by year

    Dividends and Yields

    ABBV pays out 60.94% of earnings as dividends.

    Dividend Per Share (Annual)$6.92
    Dividend Yield2.36%
    Payment ScheduleQuarterly
    Dividend Growth (3Y CAGR)+5.17%
    Dividend Growth (5Y CAGR)+6.81%
    Payout Ratio60.94%
    FCF Payout Ratio64.32%
    Earnings Yield4.39%
    FCF Yield3.64%
    Buyback Yield0.30%
    Shareholder Yield2.64%

    Full dividend history

    Peer Position

    Against 9 similar companies, ABBV has the 4th highest P/E.

    P/E Ratio22.8x vs 19.8x median
    P/S Ratio7.8x vs 4.9x median
    ROIC16.39% vs 13.16% median
    Revenue Growth (Trailing 4 Quarters, YoY)+10.68% vs +7.17% median
    Dividend Yield2.36% vs 2.39% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 9.96% and EPS growth at 27.26% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+9.96%
    EPS Growth Forecast (2Y CAGR)+27.26%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About ABBV

    What is ABBV's market cap?

    AbbVie has a market cap of $521.50B. Its enterprise value, which adds debt and subtracts cash, is $591.63B.

    What is ABBV's P/E ratio?

    AbbVie has a trailing P/E ratio of 22.8x and a forward P/E of 20.5x.

    How many shares of ABBV are outstanding?

    AbbVie has 1.77B shares outstanding. The count is up 0.00% from a year earlier.

    Does ABBV pay a dividend?

    Yes. AbbVie pays $6.92 a share a year, a dividend yield of 2.36%.

    How much debt does ABBV have?

    AbbVie has $80.90B of total debt and $10.77B of cash and equivalents, a net debt position of $70.13B.